Search

Your search keyword '"Evans, T.R. Jeffry"' showing total 203 results
Start Over Author "Evans, T.R. Jeffry"
203 results on '"Evans, T.R. Jeffry"'

1. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

Author

Sacco, Joseph J., Jackson, Richard, Corrie, Pippa, Danson, Sarah, Evans, T.R. Jeffry, Ochsenreither, Sebastian, Kumar, Satish, Goodman, Andrew, Larkin, James, Karydis, Ioannis, Steven, Neil, Lorigan, Paul, Plummer, Ruth, Patel, Poulam, Psarelli, Eftychia, Olsson-Brown, Anna, Shaw, Heather, Leyvraz, Serge, Handley, Louise, Rawcliffe, Charlotte, and Nathan, Paul

Published
2024
Full Text
View/download PDF

2. First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).

Author

Reig, Maria, primary, Evans, T.R. Jeffry, additional, Chon, Hong Jae, additional, Lim, Ho Yeong, additional, Ryu, Min-Hee, additional, Kim, Do Young, additional, Macarulla, Teresa, additional, Gomez-Martin, Carlos, additional, Moreno, Victor, additional, Haugk, Beate, additional, Ness, Thomas, additional, Baumann, Pia, additional, Bhoi, Sujata, additional, Jensen, Malene, additional, Tunblad, Karin, additional, Wallberg, Hans, additional, Oberg, Fredrik, additional, and Heo, Jeong, additional

Published
2024
Full Text
View/download PDF

3. MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).

Author

Sun, Jong-Mu, primary, Chao, Yee, additional, Kim, Sung-Bae, additional, Rha, Sun Young, additional, Evans, T.R. Jeffry, additional, Strickland, Andrew, additional, Wainberg, Zev A., additional, Chau, Ian, additional, Pelles-Avraham, Sharon, additional, Ajani, Jaffer A., additional, Malhotra, Ritu, additional, Liu, Qingyuan, additional, Li, Sijing, additional, Cha, Edward, additional, Rahalkar, Swapna, additional, Allen, Simon, additional, and Hsu, Chih-Hung, additional

Published
2024
Full Text
View/download PDF

4. Abstract PR04: Therapeutic development platform for pancreatic cancer in the UK national health service: Lessons learned and initial results from Precision-Panc

Author

Froeling, Fieke E.M., primary, Valle, Juan, additional, Upstill-Goddard, Rosie, additional, Grimwood, Paul, additional, Westwood, Paul, additional, Dreyer, Stephan B., additional, Kelly, Caroline, additional, Duthie, Fraser, additional, Dixon, Judith, additional, Bradley, Sarah, additional, Evans, T.R. Jeffry, additional, Sansom, Owen J., additional, Biankin, Andrew V., additional, and Chang, David K., additional

Published
2024
Full Text
View/download PDF

5. Supplementary Table 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

6. Data from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Author

Driscoll, David R., primary, Karim, Saadia A, primary, Sano, Makoto, primary, Gay, David M., primary, Jacob, Wright, primary, Yu, Jun, primary, Mizukami, Yusuke, primary, Gopinathan, Aarthi, primary, Jodrell, Duncan I., primary, Evans, T.R. Jeffry, primary, Bardeesy, Nabeel, primary, Hall, Michael N., primary, Quattrochi, Brian J., primary, Klimstra, David S., primary, Barry, Simon T., primary, Sansom, Owen J., primary, Lewis, Brian C., primary, and Morton, Jennifer P., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Tables 1 through 3 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Author

Driscoll, David R., primary, Karim, Saadia A, primary, Sano, Makoto, primary, Gay, David M., primary, Jacob, Wright, primary, Yu, Jun, primary, Mizukami, Yusuke, primary, Gopinathan, Aarthi, primary, Jodrell, Duncan I., primary, Evans, T.R. Jeffry, primary, Bardeesy, Nabeel, primary, Hall, Michael N., primary, Quattrochi, Brian J., primary, Klimstra, David S., primary, Barry, Simon T., primary, Sansom, Owen J., primary, Lewis, Brian C., primary, and Morton, Jennifer P., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figures 1 through 8 from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Author

Driscoll, David R., primary, Karim, Saadia A, primary, Sano, Makoto, primary, Gay, David M., primary, Jacob, Wright, primary, Yu, Jun, primary, Mizukami, Yusuke, primary, Gopinathan, Aarthi, primary, Jodrell, Duncan I., primary, Evans, T.R. Jeffry, primary, Bardeesy, Nabeel, primary, Hall, Michael N., primary, Quattrochi, Brian J., primary, Klimstra, David S., primary, Barry, Simon T., primary, Sansom, Owen J., primary, Lewis, Brian C., primary, and Morton, Jennifer P., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Fig. 1 from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Author

Puzanov, Igor, primary, Lindsay, Colin R., primary, Goff, Laura, primary, Sosman, Jeff, primary, Gilbert, Jill, primary, Berlin, Jordan, primary, Poondru, Srinivasu, primary, Simantov, Ronit, primary, Gedrich, Rich, primary, Stephens, Andrew, primary, Chan, Emily, primary, and Evans, T.R. Jeffry, primary

Published
2023
Full Text
View/download PDF

10. Supplemental Figure Legends from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Author

Driscoll, David R., primary, Karim, Saadia A, primary, Sano, Makoto, primary, Gay, David M., primary, Jacob, Wright, primary, Yu, Jun, primary, Mizukami, Yusuke, primary, Gopinathan, Aarthi, primary, Jodrell, Duncan I., primary, Evans, T.R. Jeffry, primary, Bardeesy, Nabeel, primary, Hall, Michael N., primary, Quattrochi, Brian J., primary, Klimstra, David S., primary, Barry, Simon T., primary, Sansom, Owen J., primary, Lewis, Brian C., primary, and Morton, Jennifer P., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Materials from A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Author

Puzanov, Igor, primary, Lindsay, Colin R., primary, Goff, Laura, primary, Sosman, Jeff, primary, Gilbert, Jill, primary, Berlin, Jordan, primary, Poondru, Srinivasu, primary, Simantov, Ronit, primary, Gedrich, Rich, primary, Stephens, Andrew, primary, Chan, Emily, primary, and Evans, T.R. Jeffry, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure from A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Author

Venugopal, Balaji, primary, Baird, Richard, primary, Kristeleit, Rebecca S., primary, Plummer, Ruth, primary, Cowan, Richard, primary, Stewart, Adam, primary, Fourneau, Nele, primary, Hellemans, Peter, primary, Elsayed, Yusri, primary, Mcclue, Steve, primary, Smit, Johan W., primary, Forslund, Ann, primary, Phelps, Charles, primary, Camm, John, primary, Evans, T.R. Jeffry, primary, de Bono, Johann S., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 3 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 4 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Tables and Figures from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Author

Zhu, Andrew X., primary, Kang, Yoon-Koo, primary, Rosmorduc, Olivier, primary, Evans, T.R. Jeffry, primary, Santoro, Armando, primary, Ross, Paul, primary, Gane, Edward, primary, Vogel, Arndt, primary, Jeffers, Michael, primary, Meinhardt, Gerold, primary, and Peña, Carol E.A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 8 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

18. Supplemental Methods from mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

Author

Driscoll, David R., primary, Karim, Saadia A, primary, Sano, Makoto, primary, Gay, David M., primary, Jacob, Wright, primary, Yu, Jun, primary, Mizukami, Yusuke, primary, Gopinathan, Aarthi, primary, Jodrell, Duncan I., primary, Evans, T.R. Jeffry, primary, Bardeesy, Nabeel, primary, Hall, Michael N., primary, Quattrochi, Brian J., primary, Klimstra, David S., primary, Barry, Simon T., primary, Sansom, Owen J., primary, Lewis, Brian C., primary, and Morton, Jennifer P., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 2 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 5 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 1 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 1 from A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Author

Venugopal, Balaji, primary, Baird, Richard, primary, Kristeleit, Rebecca S., primary, Plummer, Ruth, primary, Cowan, Richard, primary, Stewart, Adam, primary, Fourneau, Nele, primary, Hellemans, Peter, primary, Elsayed, Yusri, primary, Mcclue, Steve, primary, Smit, Johan W., primary, Forslund, Ann, primary, Phelps, Charles, primary, Camm, John, primary, Evans, T.R. Jeffry, primary, de Bono, Johann S., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 2 from A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Author

Venugopal, Balaji, primary, Baird, Richard, primary, Kristeleit, Rebecca S., primary, Plummer, Ruth, primary, Cowan, Richard, primary, Stewart, Adam, primary, Fourneau, Nele, primary, Hellemans, Peter, primary, Elsayed, Yusri, primary, Mcclue, Steve, primary, Smit, Johan W., primary, Forslund, Ann, primary, Phelps, Charles, primary, Camm, John, primary, Evans, T.R. Jeffry, primary, de Bono, Johann S., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Materials and Methods from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 7 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 9 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Author

Zhu, Andrew X., primary, Kang, Yoon-Koo, primary, Rosmorduc, Olivier, primary, Evans, T.R. Jeffry, primary, Santoro, Armando, primary, Ross, Paul, primary, Gane, Edward, primary, Vogel, Arndt, primary, Jeffers, Michael, primary, Meinhardt, Gerold, primary, and Peña, Carol E.A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 6 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Legend from A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Author

Venugopal, Balaji, primary, Baird, Richard, primary, Kristeleit, Rebecca S., primary, Plummer, Ruth, primary, Cowan, Richard, primary, Stewart, Adam, primary, Fourneau, Nele, primary, Hellemans, Peter, primary, Elsayed, Yusri, primary, Mcclue, Steve, primary, Smit, Johan W., primary, Forslund, Ann, primary, Phelps, Charles, primary, Camm, John, primary, Evans, T.R. Jeffry, primary, de Bono, Johann S., primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 2 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 4 from MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Author

Jamieson, Nigel B., primary, Morran, Douglas C., primary, Morton, Jennifer P., primary, Ali, Asif, primary, Dickson, Euan J., primary, Carter, C. Ross, primary, Sansom, Owen J., primary, Evans, T.R. Jeffry, primary, McKay, Colin J., primary, and Oien, Karin A., primary

Published
2023
Full Text
View/download PDF

34. Data from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Movie 5 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Movie 4 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S2 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Movie 2 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Movie 1 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Methods from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Movie 3 from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure and Movie Legends from Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer

Author

Nobis, Max, primary, McGhee, Ewan J., primary, Morton, Jennifer P., primary, Schwarz, Juliane P., primary, Karim, Saadia A., primary, Quinn, Jean, primary, Edward, Mike, primary, Campbell, Andrew D., primary, McGarry, Lynn C., primary, Evans, T.R. Jeffry, primary, Brunton, Valerie G., primary, Frame, Margaret C., primary, Carragher, Neil O., primary, Wang, Yingxiao, primary, Sansom, Owen J., primary, Timpson, Paul, primary, and Anderson, Kurt I., primary

Published
2023
Full Text
View/download PDF

43. A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Author

Evans, T.R. Jeffry, primary, Basu, Bristi, additional, Hubner, Richard, additional, Ma, Yuk Ting, additional, Meyer, Tim, additional, Palmer, Daniel H., additional, Pinato, David J. James, additional, Plummer, Elizabeth Ruth, additional, Ross, Paul J., additional, Samson, Adel, additional, Sarker, Debashis, additional, Kendall, Timothy, additional, Bellamy, Christopher, additional, Reeves, Helen L, additional, Thomson, Fiona, additional, Lawless, Claire A, additional, Stobo, Jamie, additional, Sansom, Owen J, additional, Mann, Derek A., additional, and Bird, Thomas G, additional

Published
2023
Full Text
View/download PDF

44. Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.

Author

Kudo, Masatoshi, primary, Qin, Shukui, additional, Piscaglia, Fabio, additional, Vogel, Arndt, additional, Evans, T.R. Jeffry, additional, Knox, Jennifer J., additional, López López, Carlos, additional, Ramji, Zahra, additional, Ren, Min, additional, Mody, Kalgi, additional, and Finn, Richard S., additional

Published
2022
Full Text
View/download PDF

45. A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.

Author

Gallagher, Peter F., primary, Naylor, Gregory, additional, Bashir, Saira, additional, Yan, Xiangfei, additional, Burke, David, additional, Plummer, Elizabeth Ruth, additional, Evans, T.R. Jeffry, additional, Coyle, Victoria M., additional, Clive, Sally, additional, McGuigan, Lesley, additional, Heinzmann, Kathrin, additional, Halbert, Gavin, additional, Veal, Gareth, additional, Tiplady, Eleanor, additional, Barnett, Shelby, additional, Yalla, Krishna, additional, Brook, Sue, additional, Dobbs, Nicola, additional, and Wilson, Richard H., additional

Published
2022
Full Text
View/download PDF

47. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

Author

Middleton, Mark R., primary, Hamid, Omid, additional, Shoushtari, Alexander Noor, additional, Meier, Friedegund Elke, additional, Bauer, Todd Michael, additional, Salama, April K.S., additional, Kirkwood, John M., additional, Ascierto, Paolo Antonio, additional, Lorigan, Paul, additional, Mauch, Cornelia, additional, Orloff, Marlana M., additional, Evans, T.R. Jeffry, additional, Abdullah, Shaad Essa, additional, Yuan, Yuan, additional, Mitchell, James, additional, and Hassel, Jessica Cecile, additional

Published
2022
Full Text
View/download PDF

48. A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

Author

Sharp, Adam, primary, Williams, Anja, additional, Blagden, Sarah Patricia, additional, Plummer, Elizabeth Ruth, additional, Hochhauser, Daniel, additional, Krebs, Matthew, additional, Pacey, Simon, additional, Evans, T.R. Jeffry, additional, Whelan, Sarah, additional, Nandakumar, Srinand, additional, Rogers, Seema, additional, Jameson, Katherine L., additional, Basile, Frank G., additional, De Bono, Johann S., additional, and Arkenau, Hendrik-Tobias, additional

Published
2022
Full Text
View/download PDF

49. Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.

Author

Evans, T.R. Jeffry, primary, Lakhani, Nehal J., additional, Arkenau, Hendrik-Tobias, additional, McKean, Meredith, additional, Symeonides, Stefan N., additional, Iwamoto, Fabio Massaiti, additional, Rotolo, Jim, additional, Capiaux, Gina, additional, Michel, Rob, additional, Kaesshaefer, Stephen, additional, Bexon, Alice Susannah, additional, and Falchook, Gerald Steven, additional

Published
2022
Full Text
View/download PDF

50. First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

Author

Di Giacomo, Anna Maria, primary, Santangelo, Federica, additional, Amato, Giovanni, additional, Simonetti, Elena, additional, Graham, Jill, additional, Lahn, Michael M. F., additional, van der Veen, Lars Anders, additional, Johnson, Zoe, additional, Pickering, Catherine Anne, additional, Durini, Marco, additional, Tan, Ziyang, additional, Tadepally, Lakshmikanth, additional, Brodin, Petter, additional, Occhipinti, Mariaelena, additional, Simonelli, Matteo, additional, Carlo-Stella, Carmelo, additional, Santoro, Armando, additional, Spiliopoulou, Pavlina, additional, Evans, T.R. Jeffry, additional, and Maio, Michele, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results